A Novel Synthesis of 5-HT4 Receptor Intestinal-Restrictive Bivalent Agonist: SIPI11588
Pharmaceutical Fronts · 01.09.2026 · 08 (03) · e220-e229
DOI: 10.1055/a-2908-5581 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceutical Fronts, erschienen am 01.09.2026. Verfasst von Linjie Zhang und 5 weiteren Autor:innen. Die Arbeit nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
SIPI11588 is a 5-HT4 receptor agonist with potential bioactivity that significantly enhances whole-gut and colonic transit and defecation. The original linear synthetic route, starting from 4-amino-5-chloro-2,3-dihydrobenzofuran-7-carboxylic acid (3), involving seven steps (37.91% overall yield), suffers from poor atom economy, complex purification operations, and critical stability issues, thereby limiting preclinical studies. Herein, we established a convergent approach for the synthesis of SIPI11588 on a large scale. The route begins with 4-amino-5-chloro-2,3-dihydrobenzofuran-7-carboxylic acid (3), which underwent an amide condensation to obtain tert-butyl 4-((4-amino-5-chloro-2,3-dihydrobenzofuran-7-carboxamido)methyl)piperidine -1-carboxylate (10). Subsequently, a sequence of reactions, including deprotection, nucleophilic substitution, and hydrolysis, are performed in a one-pot process to generate 6-(4-((4-amino-5-chloro-2,3-dihydrobenzofuran-7-carboxamido)methyl)piperidin-1-yl)hexanoic acid (1), which was subjected to amide condensation with 1,1'-(butane-1,4-diyl)bis(3-(2-(2-(2-aminoethoxy)ethoxy)ethyl)urea) hydrochloride (2) to achieve the target product SIPI11588 with a total yield of 39.57%. Compared with the original route, the new route shortens the process from 7 steps to 4 steps, simplifies the unit operations from 39 to 19 units, while eliminates complex processes, including frequent extraction, crystallization and column chromatography. This may represent a reliable, chromatography-free, and scalable approach suitable for preclinical development.
Zitieren
APA
Zhang, L., Zhang, W., Zhang, K., Zhang, Z., Wang, G., & Ni, F. (2026). A Novel Synthesis of 5-HT4 Receptor Intestinal-Restrictive Bivalent Agonist: SIPI11588. Pharmaceutical Fronts, 08(03), e220-e229. https://doi.org/10.1055/a-2908-5581
Vancouver
Zhang L, Zhang W, Zhang K, Zhang Z, Wang G, Ni F. A Novel Synthesis of 5-HT4 Receptor Intestinal-Restrictive Bivalent Agonist: SIPI11588. Pharmaceutical Fronts. 2026;08(03):e220-e229. doi:10.1055/a-2908-5581
BibTeX
@article{Zhang2026,
author = {Zhang, Linjie and Zhang, Wenbo and Zhang, Kunfan and Zhang, Zixue and Wang, Guan and Ni, Feng},
title = {A Novel Synthesis of 5-HT4 Receptor Intestinal-Restrictive Bivalent Agonist: SIPI11588},
journal = {Pharmaceutical Fronts},
year = {2026},
volume = {08},
number = {03},
pages = {e220--e229},
doi = {10.1055/a-2908-5581}
}
EUVIMED